中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 2
Feb.  2017
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2017  >  33(2): 272-276

Effect of Buqi Huoxue decoction on hemodynamics and liver fibrosis indices in hepatitis B patients with cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2017.02.013

  • The People's Hospital of Qingyuan District

  • Received Date: 2016-09-05
  • Published Date: 2017-02-20
    Abstract
  • Objective To investigate the effect of Buqi Huoxue decoction on hemodynamics and liver fibrosis indices in hepatitis B patients with cirrhotic portal hypertension.Methods A total of 79 patients with hepatitis B cirrhosis who were admitted to The People's Hospital of Qingyuan District from December 2013 to August 2015 were enrolled and randomly divided into study group( 41 patients) and control group( 38 patients).The patients in both groups were given oral entecavir( 0.5 mg,once a day) and bicyclol tablets( 25 mg,three times a day);the patients in the control group were given propranolol( 10 mg,three times a day) in addition,and those in the study group were given Buqi Huoxue decoction in addition.The course of treatment was 12 weeks for both groups.The hemodynamics and liver fibrosis indices were compared between the two groups before treatment and after 12 weeks of treatment.The t- test was used for comparison of continuous data between groups,and the chi- square test was used for comparison of categorical data between groups.Results After 12 weeks of treatment,both groups had significant reductions in diameter of the portal vein,diameter of the splenic vein,and portal vein flow and a significant increase in portal vein blood flow velocity( t = 3.847,4.672,3.524,5.237,3.578,3.829,3.468,and 3.673,P = 0.041,0.036,0.047,0.032,0.045,0.042,0.048,and 0.046),and the study group had significantly greater changes in these parameters compared with the control group( diameter of the portal vein:12.86 ± 2.34 mm vs 13.65 ± 2.45 mm,t = 3.725,P = 0.044;diameter of the splenic vein:9.50 ± 1.26 mm vs 11.15 ± 1.37 mm,t =- 6.672,P = 0.012;portal vein flow:1.23 ± 0.35 L / min vs 1.38 ± 0.44 L / min,t =-3.521,P = 0.047;portal vein blood flow velocity:19.50 ± 4.65 cm / s vs 17.57 ± 2.40 cm / s,t =- 6.225,P = 0.024).After 12 weeks of treatment,both groups had reductions in the four liver fibrosis indices hyaluronic acid,laminin,procollagen type Ⅲ,and collagen typeⅣ,and the study group had significantly greater reductions than the control group( hyaluronic acid:285.2 ± 53.4 μg /L vs 347.5 ± 63.4μg /L,t =- 7.252,P = 0.012;laminin:89.5 ± 25.6 μg /L vs 116.5 ± 29.7 μg /L,t =- 6.503,P = 0.018;procollagen type Ⅲ:63.5± 20.6 μg / L vs 98.7 ± 28.4 μg / L,t =- 5.279,P = 0.031;collagen type Ⅳ:85.5 ± 23.7 μg / L vs 122.5 ± 26.4 μg / L,t =- 6.977,P = 0.015).No patient experienced adverse drug reactions during the treatment.Conclusion Buqi Huoxue decoction can significantly improve hemodynamics and serum hepatic fibrosis indices in patients with cirrhotic portal hypertension.

     

    • FullText(HTML)
    • References(20)
  • [1]Experts in combined team of the Major Special Project of Ministry of Science and Technology supported by China's“Twelfth Five-Year Plan”.Management of clinical diagnosis,evaluation,and antiviral therapy for HBV-related cirrhosis[J].J Clin Hepatol,2014,30(2):99-108.(in Chinese)科技部十二五重大专项联合课题组专家.乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理[J].临床肝胆病杂志,2014,30(2):99-108.
    [2]TAN YW,YIN YM,YU XJ,et al.Influence of salvia miltiorrhizae and astragalus membranaceus on hemodynamics and liver fibrosis indexes in liver cirrhotic patients with portal hypertension[J].Chin JIntegr Tradit West Med(Chin),2001,21(5):351-353.(in Chinese)谭友文,殷玉梅,於学军,等.丹参、黄芪对肝硬化门静脉高压患者血流动力学及肝纤维化指标的影响[J].中国中西医结合杂志,2001,21(5):351-353.
    [3]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
    [4]GUO HJ,TONG XF.Observation of Zeqi decoction on hemodynamics and liver fibrosis indexes in liver cirrhosis patients with portal hypertension[J].Hebei J TCM,2015,37(1):18-21.(in Chinese)郭海军,佟雪飞.泽芪汤对肝硬化门静脉高压症患者血流动力学及肝纤维化指标的影响[J].河北中医,2015,37(1):18-21.
    [5]LI TH,JIA LY.Observation of the clinical effects of Gexia Zhuyu Decoction Jiaweifang in patients with chronic hepatitis B cirrhosis[J/CD].Chin J Liver Dis:Electronic Edition,2015,7(2):84-87.(in Chinese)李庭辉,贾利英.膈下逐瘀汤加味用于慢性乙型肝炎肝硬化患者的临床疗效观察[J/CD].中国肝脏病杂志:电子版,2015,7(2):84-87.
    [6]SHEN GW,LI Q,LIU Y.Danji Huoxue decoction on serum inflammatory and liver fibrosis degradation indexes in hepatitis B patients with cirrhosis[J].J Changchun Univ Chin Med,2016,32(6):1188-1190.(in Chinese)申广文,李强,刘颖.丹鸡活血汤对乙型肝炎肝硬化患者血清炎症指标及肝纤维化降解指标的影响[J].长春中医药大学学版,2016,32(6):1188-1190.
    [7]LI WJ,HOU S,ZHENG EZ.A study of the pharmacology and clinical effect of traditional Chinese medicine Astragalus membranaceus[J].Asia-Pacific Tradit Med,2015,11(8):109-110.(in Chinese)李文娟,侯崧,郑恩志.中药黄芪药理及临床疗效评价研究[J].亚太传统医药,2015,11(8):109-110.
    [8]LIU C,LIU P,MU YP,et al.Research development on treatment of Huangqi decoction for chronic liver disease[J].World Chin Med,2015,10(2):157-161.(in Chinese)刘畅,刘平,慕永平,等.黄芪汤治疗慢性肝病研究进展[J].世界中医药,2015,10(2):157-161.
    [9]MAI JY,WANG MF,HOU TL,et al.Inhibition of total flavonoids of astragalus on expression of fatty acid translocase and cyclooxygenase 2in rats with DMN-induced liver cirrhosis[J].J Pract Hepatol,2015,18(3):274-277.(in Chinese)麦静愔,汪美凤,候天禄,等.黄芪总黄酮抑制肝硬化大鼠肝组织脂肪酸转位酶和环氧化酶2表达[J].实用肝脏病杂志,2015,18(3):274-277.
    [10]LI XT,YAO XX,DING WY,et al.Clinical and experimental study of effects of Radix Angelicae Sinensis on hemodynamics of portal hypertension[J].Chin J Gastroenterol Hepatol,1998,7(2):158-161.(in Chinese)李校天,姚希贤,丁文元,等.当归对肝硬化门脉高压影响的临床与实验研究[J].胃肠病学和肝病学杂志,1998,7(2):158-161.
    [11]LI Y,WU WQ,ZHANG YM,et al.The effect of erigeron breviscapus on renal protein kinase C in diabetic rats[J].Chin J Nephrol,2000,16(2):89-91.(in Chinese)李英,吴文清,张益民,等.野黄芪甙原对糖尿病大鼠肾脏蛋白激酶C活性作用的研究[J].中华肾脏病杂志,2000,16(2):89-91.
    [12]ZHANG P,LIANG JS.Clinical effect of Astragalus membranaceus-Angelica sinensis mixture combined with low-molecular-weight heparin in treatment of refractory nephrotic syndrome[J].China JChin Mater Med,2005,30(17):1371-1372,1384.(in Chinese)张萍,梁劲松.黄芪当归合剂联用低分子肝素治疗难治性肾病综合征疗效观察[J].中国中药杂志,2005,30(17):1371-1372,1384.
    [13]WANG YQ.Anti-fibrosis effect of peach kernel extract and its molecular mechanism[J].J Med Theory Pract,2014,27(15):2015-2016.(in Chinese)王玉清.桃仁提取物抗肝纤维化作用及其分子机制研究[J].医学理论与实践,2014,27(15):2015-2016.
    [14]LI WZ,ZHANG XH,HUANG QS.Effect of total flavins in Carthamus tinctorius on liver function and related serological parameters in rats with liver fibrosis[J].Jiangxi J Tradit Chin Med,2014,45(10):46-48.(in Chinese)李伟镇,张旭红,黄清松.红花总黄素对肝纤维化大鼠肝功能和相关血清指标的影响[J].江西中医药,2014,45(10):46-48.
    [15]ZHANG W.Effect of Radix Paeoniae Rubra on liver fibrosis factors including ECM[J].Chin J Clin Ration Drug Use,2011,4(5A):74-75.(in Chinese)张巍.赤芍对肝纤维化因子ECM等的影响[J].临床合理用药杂志,2011,4(5A):74-75.
    [16]CHEN S,ZHANG Y,LI XS.Effects of Tetramethylpyrazine on expression of TGF-βand Smad 2/3 in hepatic fibrosis in rats[J].Chin J Gastroenterol Hepatol,2013,22(10):970-973.(in Chinese)陈爽,张艳,李孝生.川芎嗪对大鼠肝纤维化转化生长因子β1、Smad 2/3表达的影响[J].胃肠病学和肝病学杂志,2013,22(10):970-973.
    [17]ZHU JZ,XU QZ,WANG W,et al.Effects of atractylodes macrocephala on intestinal motility and gut hormones in rats with hepatic cirrhosis[J].Acad J Second Military Med Univ,2005,26(11):1307-1308.(in Chinese)朱金照,许其增,王雯,等.中药白术对肝硬化大鼠肠动力及胃肠激素的影响[J].第二军医大学学报,2005,26(11):1307-1308.
    [18]PENG SL.The research progress of saikosaponin d effects and its mechanism[J].J Jilin Med Coll,2014,35(1):66-68.(in Chinese)彭顺利.柴胡皂甙d的作用及其机制的研究进展[J].吉林医药学院学报,2014,35(1):66-68.
    [19]CHEN CH,JIN SZ,HAN MZ,et al.Research advances in saikosaponins in treatment of liver cirrhosis[J].Chin J Integr Tradit West Med Dig,2016,24(7):565-567.(in Chinese)陈传慧,金世柱,韩明子,等.柴胡皂甙治疗肝硬化的研究进展[J].中国中西医结合消化杂志,2016,24(7):565-567.
    [20]LI HZ,LIU Y,LONG SJ.The influence of Herba Artemisiae capillaris on the UDPGT activity in rat's hepat[J].Chin Tradit Patent Med,2001,23(1):45-47.(in Chinese)黎汉忠,刘义,龙盛京.茵陈对大鼠肝UDP-葡萄糖醛酸转移酶活性的影响[J].中成药,2001,23(1):45-47.
    • Relative Articles

  • Relative Articles

    [1]Yanheng DUAN, Jiaze AN. Application of near-infrared fluorescence imaging in hepatectomy of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(3): 677-683. doi: 10.3969/j.issn.1001-5256.2023.03.031
    [2]Zhilong SHI, Hao XU, Changpeng CHAI, Sijie YANG, Wence ZHOU. Clinical application value of difficulty score systems before laparoscopic liver resection[J]. Journal of Clinical Hepatology, 2021, 37(8): 1888-1893. doi: 10.3969/j.issn.1001-5256.2021.08.027
    [3]Junjun WANG, Lungen LU, Xiaobo CAI. Association between liver progenitor cells and liver regeneration[J]. Journal of Clinical Hepatology, 2021, 37(8): 1966-1969. doi: 10.3969/j.issn.1001-5256.2021.08.048
    [4]Lei WANG, Kangwei LIU, Yuling DUAN, Xinyao LI, Cijun PENG. Current status of the application of robot-assisted laparoscopic hepatectomy[J]. Journal of Clinical Hepatology, 2021, 37(11): 2732-2736. doi: 10.3969/j.issn.1001-5256.2021.11.054
    [5]Wang XueWen, Li Han, Wu YanBin, Niu HongKai, Kong LingQun, Cheng Yu. Hepatectomy as the preferred approach for radical resection of Bismuth Ⅳ hilar cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2020, 36(9): 2059-2062. doi: 10.3969/j.issn.1001-5256.2020.09.030
    [6]Zeng Qi, Shadike Apaer, Wu Jing, Nuerzhatijiang Anweier, Li Tao, Tuerhongjiang Tuxun. Left hemihepatectomy for Schnelldorfer type C polycystic liver disease: A case report[J]. Journal of Clinical Hepatology, 2020, 36(8): 1829-1831. doi: 10.3969/j.issn.1001-5256.2020.08.032
    [7]Ceng TaoFei, Chen GuangLei, Liu CaiGang, Dai ChaoLiu, Xu Feng. Mechanism of liver regeneration after associating liver partition and portal vein ligation for staged hepatectomy[J]. Journal of Clinical Hepatology, 2020, 36(10): 2344-2348. doi: 10.3969/j.issn.1001-5256.2020.10.040
    [8]Han Bing, Ding YiTao, Zhu XinHua, Wu YaFu, Tang Ning, Gao JiaLin, Dai Jun, Xu QingXiang, Cui Heng, He NingNing, Shi XiaoLei. Clinical effect and safety of enhanced recovery after surgery in laparoscopic hepatectomy[J]. Journal of Clinical Hepatology, 2018, 34(3): 567-572. doi: 10.3969/j.issn.1001-5256.2018.03.024
    [9]Li Le, Chen JinMing, Liu ZhongHua, Li Qiang, Shi Ying. Application of enhanced recovery after surgery versus traditional rehabilitation program in hepatectomy: a Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(2): 303-308. doi: 10.3969/j.issn.1001-5256.2018.02.017
    [10]Tian Zhou, Zhang JianHuai, Sun XiTai, Liu Bin, Qi FuZhen, Wang YeBo, Wu JinSheng, Gu DianHua. Experience in laparoscopic hepatectomy in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(8): 1712-1716. doi: 10.3969/j.issn.1001-5256.2018.08.024
    [11]Wang DianBei, Zhao LiJin, Tu Kui, Yu Qin. Clinical effect of anatomical hepatectomy in treatment of intrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(1): 102-105. doi: 10.3969/j.issn.1001-5256.2017.01.022
    [12]Chen Kai, Li XiangNong, Liu Kun, Nan YunGuang, Yang Jun. Clinical effect of hepatectomy versus extracapsular peeling in treatment of hepatic hemangioma[J]. Journal of Clinical Hepatology, 2017, 33(4): 699-704. doi: 10.3969/j.issn.1001-5256.2017.04.020
    [13]Liu Bin, Li WenGang, Chen FuZhen. Laparoscopic hepatectomy: the choice in the era of minimally invasive surgery[J]. Journal of Clinical Hepatology, 2017, 33(4): 643-646. doi: 10.3969/j.issn.1001-5256.2017.04.008
    [14]Han WeiJia, Shi HongBo, Chen Yu. Research progress in the role of autophagy in liver regeneration[J]. Journal of Clinical Hepatology, 2016, 32(9): 1827-1831. doi: 10.3969/j.issn.1001-5256.2016.09.044
    [15]Wang JinWei, Zhang YaMin. Research advances in methods for determination of tumor boundary in hepatectomy[J]. Journal of Clinical Hepatology, 2016, 32(2): 374-377. doi: 10.3969/j.issn.1001-5256.2016.02.039
    [16]Wu Xiao, Xia Hao, Wu Jian, Zhang Ming. Clinical experience in treatment of complex intrahepatic bile duct stones by regular hepatectomy[J]. Journal of Clinical Hepatology, 2016, 32(9): 1756-1759. doi: 10.3969/j.issn.1001-5256.2016.09.025
    [17]Zhang ShengJun, Liu MinLi, Chang Qi, Liu YongFeng. Efficacy comparison of precise and traditional liver resection in treatment of intrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2015, 31(10): 1648-1651. doi: 10.3969/j.issn.1001-5256.2015.10.022
    [18]Xu JunHui, Ding YouMing, Wang Bin, Fang HanGang. Clinical value of laparoscopic hepatectomy in liver cancer patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(6): 552-555. doi: 10.3969/j.issn.1001-5256.2014.06.019
    [19]Zhu Yu, Zhang Wei. Clinical application of absorbable clips in hepatectomy[J]. Journal of Clinical Hepatology, 2013, 29(12): 932-935. doi: 10.3969/j.issn.1001-5256.2013.12.015
    [20]Zhan YuTao, Chen HongSong, Liu Bin, Wei Lai, Wang Yu. Differentiation of rat bone marrow stem cells in liver regeneration.[J]. Journal of Clinical Hepatology, 2006, 22(2): 121-122.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(1)

    1. 许永宁，黄雪桓，唐芷盼，李若涵，秦雯. 2型糖尿病胰腺癌裸鼠模型的建立及活体成像观察. 临床肝胆病杂志. 2024(06): 1231-1239 . 本站查看

    Other cited types(0)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0405101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 6.4 %FULLTEXT: 6.4 %META: 91.3 %META: 91.3 %PDF: 2.3 %PDF: 2.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.4 %其他: 4.4 %其他: 0.5 %其他: 0.5 %India: 0.3 %India: 0.3 %[]: 0.8 %[]: 0.8 %上海: 3.1 %上海: 3.1 %北京: 6.9 %北京: 6.9 %南宁: 0.8 %南宁: 0.8 %台州: 0.3 %台州: 0.3 %吉林: 1.0 %吉林: 1.0 %唐格朗: 0.3 %唐格朗: 0.3 %张家口: 2.8 %张家口: 2.8 %杭州: 0.8 %杭州: 0.8 %百色: 0.5 %百色: 0.5 %石家庄: 0.8 %石家庄: 0.8 %美国伊利诺斯芝加哥: 0.3 %美国伊利诺斯芝加哥: 0.3 %芒廷维尤: 33.4 %芒廷维尤: 33.4 %苏州: 0.3 %苏州: 0.3 %莫斯科: 1.3 %莫斯科: 1.3 %西宁: 40.9 %西宁: 40.9 %金华: 0.3 %金华: 0.3 %长春: 0.5 %长春: 0.5 %其他其他India[]上海北京南宁台州吉林唐格朗张家口杭州百色石家庄美国伊利诺斯芝加哥芒廷维尤苏州莫斯科西宁金华长春

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2342) PDF downloads(406) Cited by(1)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2183]YesterdayPV[4802]TodayIP[351]TodayPV[617]Online[37]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return